Fecal microbiota transplantation for recurrent Clostridioides difficile infection

Haber, Stacy L.; Raney, Carrington R. K.; Larson, Trent; Lau, Jennifer Park

doi:10.1093/ajhp/zxz078

Cited by 6 publications

(2 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Dietary fiber can be metabolized and fermented by intestinal bacteria into SCFAs, including acetic acid, propionic acid and butyric acid, which may also be involved in the pathogenesis of metabolic diseases[ 32 ]. The types and quantities of SCFAs are thought to vary with the composition of intestinal microbes.…”

Section: Fmt and Metabolic Diseasesmentioning

confidence: 99%

Fecal microbiota transplantation in the metabolic diseases: Current status and perspectives

Ji¹,

Wen²,

Duan³

2022

WJG

View full text Add to dashboard Cite

With the development of microbiology and metabolomics, the relationship between the intestinal microbiome and intestinal diseases has been revealed. Fecal microbiota transplantation (FMT), as a new treatment method, can affect the course of many chronic diseases such as metabolic syndrome, malignant tumor, autoimmune disease and nervous system disease. Although the mechanism of action of FMT is now well understood, there is some controversy in metabolic diseases, so its clinical application may be limited. Microflora transplantation is recommended by clinical medical guidelines and consensus for the treatment of recurrent or refractory Clostridium difficile infection, and has been gradually promoted for the treatment of other intestinal and extraintestinal diseases. However, the initial results are varied, suggesting that the heterogeneity of the donor stools may affect the efficacy of FMT. The success of FMT depends on the microbial diversity and composition of donor feces. Therefore, clinical trials may fail due to the selection of ineffective donors, and not to faulty indication selection for FMT. A new understanding is that FMT not only improves insulin sensitivity, but may also alter the natural course of type 1 diabetes by modulating autoimmunity. In this review, we focus on the main mechanisms and deficiencies of FMT, and explore the optimal design of FMT research, especially in the field of cardiometabolic diseases.

show abstract

Section: Fmt and Metabolic Diseasesmentioning

confidence: 99%

Fecal microbiota transplantation in the metabolic diseases: Current status and perspectives

Ji¹,

Wen²,

Duan³

2022

WJG

View full text Add to dashboard Cite

show abstract

“…Moreover, although no guidelines have included them among suggested methods to prevent CD infection and disease, probiotics have been considered by some authors a potential measure in this regard [ 19 ]. Finally, attempts to use fecal transplantation [ 20 ] and to develop vaccines have been made [ 21 ]. In this narrative review, the present possibilities of CDI prevention will be discussed.…”

Section: Introductionmentioning

confidence: 99%

Prevention of Clostridium difficile Infection and Associated Diarrhea: An Unsolved Problem

et al. 2020

View full text Add to dashboard Cite

For many years, it has been known that Clostridium difficile (CD) is the primary cause of health-care-associated infectious diarrhea, afflicting approximately 1% of hospitalized patients. CD may be simply carried or lead to a mild disease, but in a relevant number of patients, it can cause a very severe, potentially fatal, disease. In this narrative review, the present possibilities of CD infection (CDI) prevention will be discussed. Interventions usually recommended for infection control and prevention can be effective in reducing CDI incidence. However, in order to overcome limitations of these measures and reduce the risk of new CDI episodes, novel strategies have been developed. As most of the cases of CDI follow antibiotic use, attempts to rationalize antibiotic prescriptions have been implemented. Moreover, to reconstitute normal gut microbiota composition and suppress CD colonization in patients given antimicrobial drugs, administration of probiotics has been suggested. Finally, active and passive immunization has been studied. Vaccines containing inactivated CD toxins or components of CD spores have been studied. Passive immunization with monoclonal antibodies against CD toxins or the administration of hyperimmune whey derived from colostrum or breast milk from immunized cows has been tried. However, most advanced methods have significant limitations as they cannot prevent colonization and development of primary CDI. Only the availability of vaccines able to face these problems can allow a resolutive approach to the total burden due to this pathogen.

show abstract

Association between the gut and oral microbiome with obesity

Benahmed¹,

Gasmi

Doşa

et al. 2021

Anaerobe

View full text Add to dashboard Cite

Fecal microbiota transplantation for recurrent Clostridioides difficile infection

Cited by 6 publications

References 19 publications

Fecal microbiota transplantation in the metabolic diseases: Current status and perspectives

Fecal microbiota transplantation in the metabolic diseases: Current status and perspectives

Prevention of Clostridium difficile Infection and Associated Diarrhea: An Unsolved Problem

Association between the gut and oral microbiome with obesity

Contact Info

Product

Resources

About